



Epoetin Alfa

Revised: February 7, 2019.

CASRN: 113427-24-0

Drug Levels and Effects

Summary of Use during Lactation

The excretion of exogenous epoetin alfa (recombinant human erythropoietin; EPO) in breastmilk has not been studied. Erythropoietin is a normal component of human milk. Although some studies have shown an improve response of postpartum anemia when epoetin alfa was used with iron therapy, current consensus is that epoetin alfa has no clinically important effect on the increase in hemoglobin concentration over iron alone.[1] No adverse reactions were reported in the breastfed infants of mothers who received epoetin alfa. Based on theoretical considerations, the manufacturer recommends avoiding the use of epoetin alfa multiple-dose vials for lactating women because of its benzyl alcohol content and to avoid breastfeeding for 2 weeks after a dose that contains benzyl alcohol. No special precautions are required during breastfeeding if mothers receive epoetin alfa from a single-use vial without preservatives.[2]

Some authors have hypothesized that erythropoietin in milk might help maintain the integrity of the lining of the mammary epithelium and the infant gastrointestinal tract, thereby reducing the risk of mother-to-child transmission of HIV infection (MTCT).[3] A case-control study in Tanzania supports the protective role of erythropoietin in breastmilk against MTCT.[4] Erythropoietin might also have a modest beneficial effect on the infant's red cell production.[5] Holder pasteurization (62.5 degrees C for 30 minutes) decreases the concentration of endogenous erythropoietin by an average about 75%, with complete degradation in some samples.[6]

A study on Holder pasteurization of breastmilk found that the erythropoietin concentration in breastmilk dropped from about 1.9 international units/L before pasteurization to about 0.5 international units/L after pasteurization.[6]

Drug Levels

Maternal Levels. Relevant published information on exogenous administration of epoetin alfa was not found as of the revision date. However, breastmilk normally contains erythropoietin. Erythropoietin concentrations in human milk are in the range of approximately 4 to 5 units/L in the first 1 to 2 months postpartum and increase to 20 to 40 units/L by the third month and to 100 to 150 units/L by 12 months.[3]

Infant Levels. Published information on absorption of epoetin alfa from breastmilk was not found as of the revision date. However, several studies in which oral doses of epoetin alfa and other recombinant forms of erythropoietin were given to preterm infants found that epoetin is absorbed to a small extent. Increases in hematocrit in infants treated with oral epoetin alfa have been small to negligible.[5][7][8][9][10][11] However, one study found that hospitalized preterm infants taking enteral feedings and given 400 units daily of recombinant human erythropoietin by mouth with ferrous sulfate had higher reticulocyte counts and serum erythropoietin concentrations upon hospital discharge than control infants given only ferrous sulfate.[12]

Effects in Breastfed Infants

Enhancement of gastrointestinal tract maturation has been proposed as a function of erythropoietin in breastmilk.[3][12]

In a study of 40 women with postpartum anemia, 19 of 20 women who received iron and subcutaneous recombinant human erythropoietin (generic name and brand not specified) 200 IU/kg daily for 15 days were able to breastfeed their infants. This regimen is more aggressive than the approved three times/week regimen. In the control group that received only oral iron and folic acid, only 10 were able to breastfeed their infants. No adverse reactions were reported among the infants of women who receive epoetin.[2]

Effects on Lactation and Breastmilk

In small studies, epoetin alfa administration decreased serum prolactin in patients with amyotrophic lateral sclerosis,[13] but had no effect in normal subjects or in patients with renal failure undergoing chronic ambulatory peritoneal dialysis.[14][15] The prolactin level in a mother with established lactation may not affect her ability to breastfeed.

References

1. Milman N. Postpartum anemia II: Prevention and treatment. *Ann Hematol.* 2012;91:143-54. PubMed PMID: 22160256.
2. Makrydimas G, Lolis D, Lialios G et al. Recombinant human erythropoietin treatment of postpartum anemia. Preliminary results. *Eur J Obstet Gynecol Reprod Biol.* 1998;81:27-31. PubMed PMID: 9846709.
3. Semba RD, Juul SE. Erythropoietin in human milk: Physiology and role in infant health. *J Hum Lact.* 2002;18:252-61. PubMed PMID: 12192960.
4. Arsenault JE, Webb AL, Koulinska IN et al. Association between breast milk erythropoietin and reduced risk of mother-to-child transmission of HIV. *J Infect Dis.* 2010;202:370-3. PubMed PMID: 20557236.
5. Pasha YZ, Ahmadpolir-Kacho M, Hajiahmadi M, Hosseini M. Enteral erythropoietin increases plasma erythropoietin level in preterm infants: A randomized controlled trial. *Indian Pediatr.* 2008;45:25-8. PubMed PMID: 18250501.
6. Untalan PB, Keeney SE, Palkowetz KH et al. Heat susceptibility of interleukin-10 and other cytokines in donor human milk. *Breastfeed Med.* 2009;4:137-44. PubMed PMID: 19366315.
7. Calhoun DA, Christensen RD. Hematopoietic growth factors in neonatal medicine: The use of enterally administered hematopoietic growth factors in the neonatal intensive care unit. *Clin Perinatol.* 2004;31:169-82. PubMed PMID: 15183665.
8. Ballin A, Bilker-Reich A, Arbel E et al. Erythropoietin, given enterally, stimulates erythropoiesis in premature infants. *Lancet.* 1999;353:1849. Letter. PubMed PMID: 10359412.
9. Juul SE. Enterally doses recombinant human erythropoietin does not stimulate erythropoiesis in neonates. *J Pediatr.* 2003;143:321-6. PubMed PMID: 14517513.
10. Juul SE, Cristensen RD. Absorption of enteral recombinant human erythropoietin by neonates. *Ann Pharmacother.* 2003;37:782-6. PubMed PMID: 12773061.

11. Britton JR, Christensen RD. Enteral administration of recombinant erythropoietin to preterm infants. *J Perinatol*. 1995;15:281-3. PubMed PMID: 8558334.
12. Miller M, Iliff P, Stoltzfus RJ, Humphrey J. Breastmilk erythropoietin and mother-to-child HIV transmission through breastmilk. *Lancet*. 2002;360:1246-8. PubMed PMID: 12401271.
13. Tokgoz B, Utas C, Dogukan A et al. Influence of long term erythropoietin therapy on the hypothalamic-pituitary-thyroid axis in patients undergoing CAPD. *Ren Fail*. 2002;24:315-23. PubMed PMID: 12166698.
14. Bernini GP, Mariotti F, Brogi G et al. Effects of erythropoietin administration on prolactin secretion in normal subjects. *Nephron*. 1993;65:522-6. PubMed PMID: 8302403.
15. Markianos M, Kosmidis ML, Sfagos C. Reductions in plasma prolactin during acute erythropoietin administration. *Neuro Endocrinol Lett*. 2006;27:355-8. PubMed PMID: 16816832.

Substance Identification

Substance Name

Epoetin Alfa

CAS Registry Number

113427-24-0

Drug Class

Breast Feeding

Lactation

Colony-Stimulating Factors

Hematinics

Hematopoietic Cell Growth Factors